REDWOOD CITY, Calif.,
Feb. 23, 2017 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of moderate-to-severe acute
pain, announced that it will release fourth quarter and yearly
financial results after market close on Thursday, March 2nd, 2017. AcelRx management will
host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 2nd 2017 to discuss the
financial results and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. An NDA for
DSUVIA™ (sufentanil sublingual tablet, 30mcg) with a proposed
indication for the treatment of moderate-to-severe acute pain in
medically supervised settings, was submitted to the FDA for review
in December 2016.
The Company's follow on product, ZALVISO® (sufentanil sublingual
tablet system), designed for the management of moderate-to-severe
acute pain in adult patients in the hospital setting, is currently
enrolling patients in a Phase 3 clinical trial, IAP312. ZALVISO
delivers 15 mcg sufentanil sublingually through a non-invasive
delivery route via a pre-programmed, patient-controlled analgesia
device. ZALVISO is approved in the EU and is investigational and in
late-stage development in the U.S. Grunenthal Group holds the
rights for ZALVISO in Europe,
where a commercial launch has begun.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward-Looking Statements
This press
release contains forward-looking statements, including, but not
limited to, statements related to the process and timing of
anticipated future development of AcelRx's product candidates,
DSUVIATM (sufentanil sublingual tablet, 30 mcg), known
as ARX-04 outside the United
States, and ZALVISO® (sufentanil sublingual tablet system),
including U.S. Food and Drug Administration, or FDA, review of the
New Drug Application, or NDA, for DSUVIA; the potential approval of
the DSUVIA NDA by the FDA; the DSUVIA and ARX-04 clinical trial
results; AcelRx's pathway forward towards gaining approval of
ZALVISO in the U.S., including successful completion of the IAP312
clinical study for ZALVISO; and the therapeutic and commercial
potential of AcelRx's product candidates, including potential
market opportunities for DSUVIA, ARX-04 and ZALVISO. These
forward-looking statements are based on AcelRx Pharmaceuticals'
current expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and timing of
events could differ materially from those anticipated in such
forward-looking statements, and as a result of these risks and
uncertainties, which include, without limitation, risks related to
AcelRx Pharmaceuticals' DSUVIA and ARX-04 development programs,
including the FDA review of the DSUVIA NDA and the possibility that
the FDA may dispute or interpret differently clinical results
obtained from the DSUVIA Phase 3 studies; the ZALVISO development
program, including successful completion of IAP312 and the
resubmission of the ZALVISO NDA to the FDA; any delays or inability
to obtain and maintain regulatory approval of its product
candidates, including DSUVIA in the
United States, ARX-04 in Europe and ZALVISO in the United States; the uncertain clinical
development process; the success, cost and timing of all
development activities and clinical trials; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q filed with the SEC on
November 2, 2016. AcelRx undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-hold-annual-2016-financial-results-conference-call-and-webcast-on-thursday-march-2nd-2017-300412731.html
SOURCE AcelRx Pharmaceuticals, Inc.